Skip to main content
Premium Trial:

Request an Annual Quote

PatternAg Closes $35M Series B Financing Round

NEW YORK – Agricultural technology company PatternAg said on Thursday that it has closed a $35 million Series B funding round.

The round was led by Conti Ventures, with additional investment from Bidra Innovations. Existing investors, including The Production Board, Valor Capital Group, Founders Fund, iSelect, LAUNCH, and Ospraie Ag Science, also joined the round.

Based in Emeryville, California, PatternAg said its metagenomics platform provides data-driven, evidence-based, and long-term predictions about crop risks and nutrient deficiencies at scale in row crops.

The company provides predictive soil analytics that track pest, pathogen, fertility, and nutrient levels for corn and soybean growers across the Midwest, helping farmers predict and plan crop protection, seed selection, and fertility decisions for the upcoming season while controlling input costs.

PatternAg said the Series B funding, which brings the company’s total funding to $60 million, will help expand its intellectual property portfolio that already includes the ​​largest soil metagenomics dataset in the global agriculture industry.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.